Ritchlin CT, et al. Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. ACR 2018, abstract L17.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
feb 2019 | ILD, Pneumonie, RA